The asx does not rate medtech like the NASDAQ does.I am into AVR as well and they are going to the NASDAQ in the next 6 months as per their agm in order to raise more money and not to be confined by a 15% asx ruling. If they gain 5% of the $10b market they are in and be priced as per their rivals they would have a SP of $600. Presently $19. They like EYE have a better product than the market leader Edwards science as per the data.
Nova Eye Medical (EYE) Discussion, page-2989
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.003(1.33%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.5¢ | 19.0¢ | $25.79K | 133.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 156918 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 143255 | 4 |
View Market Depth
| Last trade - 11.07am 09/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |